NC
CLBT icon

nVerses Capital’s Cellebrite CLBT Stock Holding History

nVerses Capital’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,600
Closed -$103K – 1057
2024
Q2 		$103K Buy
+8,600
New +$96.1K 0.06% 441

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

nVerses Capital's CLBT Position: Q3 2024 in Review

nVerses Capital sold out of Cellebrite (CLBT) in Q3 2024, closing a stake of 8,600 shares — an estimated $103K sold.

nVerses Capital first reported a position in CLBT in Q2 2024 and held it in 1 quarter. The position peaked at $103K in Q2 2024. 164 funds tracked by Wall St. Rank hold CLBT as of Q3 2024.

  • nVerses Capital reported no remaining Cellebrite position as of Q3 2024 after selling out during the quarter.
  • nVerses Capital sold 8,600 Cellebrite shares in Q3 2024, an estimated $103K.
  • nVerses Capital first reported a position in Cellebrite in Q2 2024 and held it in 1 quarter.
  • nVerses Capital's Cellebrite position peaked at $103K in Q2 2024.
  • 164 funds tracked by Wall St. Rank held Cellebrite as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.